Known targets — ChEMBL curated mechanism
The experimentally established mechanism targets of Torsemide. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TBXA2R | P21731 | 10/20 | 0.98 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.98 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.98 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.98 |
| ▸ | HIF1A | Q16665 | 1/20 | 0.98 |
| ▸ | PTGS1 | P23219 | 2/20 | 0.52 |
| ▸ | PTGS2 | P35354 | 2/20 | 0.52 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.52 |
| ▸ | BRS3 | P32247 | 4/20 | 0.51 |
| ▸ | MAPT | P10636 | 1/20 | 0.50 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Torsemide SCHEMBL22687888 | 0.99 | TBXA2R (0.96) | TBXA2RKDM4ECYP3A4CYP2C9HIF1A | |
| Torsemide SCHEMBL41184 | 0.99 | TBXA2R (1.00) | TBXA2RKDM4ECYP3A4CYP2C9HIF1A | |
| Torsemide SCHEMBL29369134 | 0.99 | TBXA2R (1.00) | TBXA2RKDM4ECYP3A4CYP2C9HIF1A | |
| Torsemide SCHEMBL29395363 | 0.99 | TBXA2R (1.00) | TBXA2RKDM4ECYP3A4CYP2C9HIF1A | |
| Torsemide SCHEMBL4015063 | 0.99 | TBXA2R (1.00) | TBXA2RKDM4ECYP3A4CYP2C9HIF1A | |
| Torsemide SCHEMBL28460508 | 0.98 | TBXA2R (0.98) | TBXA2RKDM4ECYP3A4CYP2C9HIF1A | |
| Torsemide SCHEMBL6315139 | 0.98 | TBXA2R (0.98) | TBXA2RKDM4ECYP3A4CYP2C9HIF1A | |
| Torsemide SCHEMBL4827506 | 0.98 | TBXA2R (0.98) | TBXA2RKDM4ECYP3A4CYP2C9HIF1A | |
| Torsemide SCHEMBL6307778 | 0.98 | TBXA2R (0.98) | TBXA2RKDM4ECYP3A4CYP2C9HIF1A | |
| Torsemide SCHEMBL7256454 | 0.97 | TBXA2R (0.96) | TBXA2RKDM4ECYP3A4CYP2C9HIF1A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 11 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-110606826-B | Torasemide sodium monohydrate, crystal forms and compositions thereof | 上海勋和医药科技有限公司 | 2021-06-01 | — | — | CN | claimed |
| WO-2020233288-A1 | TORSEMIDE SODIUM MONOHYDRATE, CRYSTAL FORM THEREOF AND COMPOSITION THEREOF | 上海勋和医药科技有限公司 (CN) | 2020-11-26 | — | — | WO | claimed |
| CN-110606826-A | Torasemide sodium monohydrate, crystal forms and compositions thereof | 上海勋和医药科技有限公司 | 2019-12-24 | — | — | CN | claimed |
| WO-2024151502-A1 | METHODS OF TREATMENT USING LOOP DIURETICS | SCPHARMACEUTICALS INC. (US) | 2024-07-18 | — | — | WO | disclosed |
| WO-2024064027-A1 | LIQUID PHARMACEUTICAL FORMULATIONS OF LOOP DIURETICS AND METHODS OF ADMINISTERING THE SAME | SCPHARMACEUTICALS INC. (US) | 2024-03-28 | — | — | WO | disclosed |
| CN-110606826-B | Torasemide sodium monohydrate, crystal forms and compositions thereof | 上海勋和医药科技有限公司 | 2021-06-01 | — | — | CN | disclosed |
| WO-2020233288-A1 | TORSEMIDE SODIUM MONOHYDRATE, CRYSTAL FORM THEREOF AND COMPOSITION THEREOF | 上海勋和医药科技有限公司 (CN) | 2020-11-26 | — | — | WO | disclosed |
| CN-110606826-A | Torasemide sodium monohydrate, crystal forms and compositions thereof | 上海勋和医药科技有限公司 | 2019-12-24 | — | — | CN | disclosed |
| US-7378527-B2 | Process for the preparation of torsemide and related intermediates | APOTEX PHARMACHEM INC (CA) | 2008-05-27 | — | — | US | disclosed |
| US-20050209460-A1 | Process for the preparation of torsemide and related intermediates | BRANTFORD CHEMICALS INC. | 2005-09-22 | — | — | US | disclosed |
| US-4861786-A | Composition for a stable vein compatible injectable solution of torasemide process for the preparation and method of use | BOEHRINGER MANNHEIM GMBH (DE) | 1989-08-29 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050209460-A1 | Process for the preparation of torsemide and related intermediates | TNNI3, ALK, TNNT2 | TBXA2R 1559/4885KDM4E 2731/4885CYP3A4 34/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.